NCT01312441

Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Albany College of Pharmacy and Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The prevalence of vitamin D deficiency increases as kidney function declines. As a result, many hemodialysis patients often have low levels of vitamin D. Recent evidence has shown that vitamin D supplementation may improve many aspects of poor health such as heart disease and inflammatory markers. The objectives of this study are to determine how supplementing dialysis patients with ergocalciferol increases vitamin D levels, how long vitamin D levels can be maintained after a 6 month treatment course, and to examine the effect of ergocalciferol on biomarkers of inflammation and vascular health.

Conditions

• Vitamin D Deficiency
• Renal Failure Chronic Requiring Hemodialysis

Interventions

Type	Name	Description
DRUG	Ergocalciferol	Ergocalciferol capsules 50,000 IU once weekly for 6 months
DRUG	Placebo	Placebo by mouth once weekly for 6 months

Timeline

• Start date: 2011-01-01
• Primary completion: 2015-06-01
• Completion: 2015-08-01
• First posted: 2011-03-10
• Last updated: 2016-01-14

Locations

4 sites across 1 country: United States